It for intravenous use is a combination of imipenem,a penem antibacterial,and cilastatin,a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: ? Lower respiratory tract infections. ? Urinary tract infections. ? Intra-abdominal infections. ? Gynecologic infections. ? Bacterial septicemia. ? Bone and joint infections. ? Skin and skin structure infections. ? Endocarditis
This is a combined preparation of Imipenem and Cilastatin. Imipenem is a penem antibacterial drug. Cilastatin sodium is a renal dehydropeptidase inhibitor that limits the renal metabolism of imipenem. The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of Escherichia coli, and 1A, 1B, 2, 4 and 5 of Pseudomonas aeruginosa. The lethal effect is related to binding to PBP 2 and PBP 1B. Imipenem has a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases produced by Gram-negative and Gram-positive bacteria. It is a potent inhibitor of betalactamases from certain Gram-negative bacteria which are inherently resistant to most beta-lactam antibacterials, e.g., Pseudomonas aeruginosa, Serratia spp., and Enterobacter spp.
The dosage of It in adult patients should be based on suspected or confirmed pathogen susceptibility. ? For adult patients with normal renal function (creatinine clearance of greater than or equal to 90 mL/min),the recommended dosage regimens are: 500 mg every 6 hours OR 1000 mg every 8 hours OR 1000 mg every 6 hours . ? See full prescribing information for dosage recommendations in pediatric patients. ? A reduction in dose must be made for a patient with a creatinine clearance of less than 90 mL/min . ? Patients with creatinine clearances of less than 15 mL/min should not receive It unless hemodialysis is instituted within 48 hours . ? Reconstitute It vial with appropriate diluent and dilute the reconstituted suspension with an appropriate infusion solution before administering by intravenous infusion .
Concurrent admin with probenecid may increase the half-life of cilastatin. Increased risk of generalised seizures when used concurrently with ganciclovir.
Contraindicated in patients who have demonstrated hypersensitivity to this product.
Phlebitis,nausea,diarrhea,vomiting,rash,pain injection site, fever,hypotension,seizures,erythema at injection site,dizziness, pruritus,vein induration,urticaria,somnolence.
Pregnancy: Category C. There are no adequate and well controlled studies in pregnant women. Cispenam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Imipenem has been detected in human milk. If the use of Cispenam is deemed essential,the patient should stop nursing.
In the case of overdosage, discontinue PRIMAXIN, treat symptomatically, and institute supportive
measures as required. PRIMAXIN is hemodialyzable
Store at or below 25° C temperature. Keep away from light and wet place. Keep out of reach of children.
.png&w=384&q=75)